Medicinal liquid preparation, dry powder preparation and preparation method thereof
A liquid and dry powder preparation for ADCs using surfactants and protective agents with a buffer system stabilizes proteins, addressing stability issues and ensuring high quality and safety.
Patent Information
- Application Number
- CN202411198080.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-03
AI Technical Summary
Maintaining the chemical and physical stability of pharmaceutical proteins, particularly antibody-drug conjugates (ADCs), is challenging due to factors like oxidation, isomerization, denaturation, and aggregation, which affect efficacy and safety, and there are no Claudin18.2-targeted drugs on the market for gastric cancer.
A liquid pharmaceutical preparation containing a drug, a surfactant (polysorbate 20 or 80), a protective agent (trehalose, mannitol, sodium chloride, arginine hydrochloride, proline, or glycine), and a buffer salt system (histidine/histidine hydrochloride) stabilizes the protein molecules, while a dry powder preparation is achieved through freeze-drying the liquid preparation in specific stages.
The preparations maintain structural stability of protein molecules, reduce degradation, and ensure high quality with minimal impurities, achieving stability under various conditions and meeting quality standards.
Smart Images

Figure BDA0005017072700000081 
Figure BDA0005017072700000082 
Figure BDA0005017072700000091
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical preparations, and more specifically, to a liquid preparation, a dry powder preparation of a drug containing protein molecules (such as an antibody-drug conjugate) and a preparation method thereof. Background Art
[0002] Maintaining the chemical and physical stability of pharmaceutical proteins (e.g., antibodies) is a huge challenge during the production and product lifecycle of therapeutic drugs (e.g., anticancer drugs). Chemical instability of proteins can be caused by oxidation, isomerization, deamidation, and disulfide bond reorganization, while physical instability refers to degradation caused by denaturation, surface adsorption, and aggregation. These changes can affect subsequent efficacy and safety. Exposure of hydrophobic surfaces of proteins can cause protein-protein interactions, leading to the formation of aggregates. Especially in the case of antibody-drug conjugates (ADCs), ADCs have higher hydrophobicity after conjugation with MMAE (Log P ≈ 3.1) than unconjugated antibodies. In addition to protein interactions, factors such as protein concentration, temperature, agitation, and ionic strength can also cause protein aggregation. In addition, after drug conjugation, in addition to changes in hydrophobicity, conjugation of interchain cysteines can also lead to the formation of aggregates during manufacturing and storage. In addition, conjugation of large hydrophobic groups may also destroy the local secondary and tertiary structures of proteins. Therefore, how to improve the stability of drug preparations containing protein components (such as antibodies), especially antibody-conjugated drug preparations, is one of the problems to be solved urgently in this field.
[0003] Gastric cancer is a common cancer. Currently, about 90% of gastric cancers found in my country are in the advanced stage. Even if advanced gastric cancer patients receive surgical treatment, the 5-year survival rate is only about 5%-20%. The median overall survival (OS) of patients with advanced gastric cancer is about 10 months. Claudin18.2 protein is only expressed in differentiated gastric mucosal epithelial cells, but it is often abnormally highly expressed in a variety of digestive system malignancies.
[0004] Currently, there is no Claudin18.2-targeted drug on the market in the world. The drug under investigation, Claudiximab, has progressed to Phase III clinical trials. Phase II clinical data showed that in patients with Claudin18.2-positive gastroesophageal cancer, the combination of Claudin18.2 human-mouse chimeric monoclonal antibody Claudiximab and first-line chemotherapy drugs has clinically relevant benefits in terms of progression-free survival (PFS) and overall survival (OS). According to existing data, the Claudin18.2 ADC molecule has significant efficacy and can significantly inhibit tumor growth.
[0005] The contents of the background technology section are merely the technologies known to the inventors and do not necessarily represent the prior art in the field. Summary of the invention
[0006] In view of the deficiencies in the prior art, the object of the present invention is to provide a pharmaceutical preparation and a preparation method and application thereof, and in particular to provide a liquid preparation of a drug (such as ADC) containing a protein component (such as an antibody) and a preparation method thereof, and a dry powder preparation of a drug and a preparation method thereof.
[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0008] On the one hand, the present invention discloses a liquid pharmaceutical preparation, comprising a drug, an auxiliary component and water, wherein the auxiliary component comprises a surfactant, a protective agent and optionally a buffer salt system, wherein the drug is a drug containing a protein molecule, preferably an antibody, and more preferably an antibody-drug conjugate (ADC).
[0009] The liquid drug preparation of the present invention uses a protective agent and a surfactant in combination as a stability protective agent for the drug, which helps to keep the protein molecules of the drug structurally stable in the liquid preparation and prevent them from being easily degraded.
[0010] Furthermore, the surfactant is selected from one or both of polysorbate 20 and polysorbate 80.
[0011] Furthermore, the protective agent is selected from one of trehalose, mannitol, sodium chloride, arginine hydrochloride, proline, glycine and a mixture thereof.
[0012] Furthermore, the protective agent preferably comprises sucrose.
[0013] Furthermore, the buffer salt system is selected from a phosphate buffer system, a citrate buffer system, a succinate buffer system and a histidine / histidine hydrochloride buffer system.
[0014] Furthermore, the buffer salt system is a histidine / histidine hydrochloride buffer system.
[0015] Furthermore, in the preparation, the protein concentration of the drug is 5-30 mg / mL, preferably, the protective agent concentration is 120-240 mmol / L, preferably, the surfactant concentration is 0.1-0.5 mg / mL, preferably, the buffer salt concentration is 5-15 mmol / L.
[0016] Furthermore, the liquid preparation contains, in terms of protein concentration, 10-20 mg / mL (e.g., 20 mg / mL) of antibody-drug conjugate, 180-220 (e.g., 200) mmol / L of sucrose, 0.15-0.3 (e.g., 0.2) mg / mL of polysorbate 80, and 8-12 (e.g., 10) mmol / L of histidine / histidine hydrochloride.
[0017] Furthermore, the pH of the liquid preparation is 4.5-6.5, for example, the pH is 5.0-6.0, 4.8-5.8, for example, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6.
[0018] Furthermore, the drug is an antibody-drug conjugate (ADC).
[0019] Further, the Claudin18.2 ADC.
[0020] On the other hand, the present invention relates to a method for preparing a liquid pharmaceutical preparation, which comprises mixing the drug with the above-mentioned auxiliary material components and water.
[0021] On the other hand, the present invention relates to a dry powder preparation, wherein the dry powder preparation comprises the above-mentioned drug and excipient components, preferably, the dry powder preparation is prepared by drying (for example, freeze-drying) the above-mentioned drug liquid preparation.
[0022] On the other hand, the present invention discloses a method for preparing a dry powder preparation, comprising the following steps: freeze-drying the liquid drug preparation according to any one of claims 1 to 5.
[0023] Furthermore, the freeze-drying includes: a first pre-freezing stage, a second pre-freezing stage, a third pre-freezing stage (annealing), a fourth pre-freezing stage, a first drying stage, a second drying stage, secondary drying, a pressure rise test and a gas filling step.
[0024] Preferably, the gas in the gas filling step is nitrogen or air.
[0025] According to the dry powder preparation method of the present invention, the product appearance obtained by freeze-drying is good, and the moisture content is low. The appearance is still good after redissolution. In addition, the product has good stability (such as high temperature, light stability), and after thermal acceleration test, various quality parameters such as protein concentration, SEC (size exclusion chromatography) purity, nrCE-SDS (non-reduced sodium dodecyl sulfate capillary gel electrophoresis) purity, iCIEF (capillary isoelectric focusing electrophoresis), DAR value (antibody drug coupling ratio), moisture and visible foreign matter, insoluble particles, etc., have no obvious changes, meet quality standards.
[0026] Further, according to the liquid preparation or lyophilized preparation involved in the present invention, the protective agent helps to stabilize the structure of the protein component in the drug, is not easy to degrade, and has fewer impurities in the preparation. Further, the combined use of the protective agent and the surfactant can further promote structural stability and even show a more significant synergistic effect. Further adding a buffer salt system makes the liquid preparation more stable within a certain pH range. DETAILED DESCRIPTION
[0027] In the following description, only certain exemplary embodiments are briefly described. As those skilled in the art will appreciate, the described embodiments may be modified in various ways without departing from the spirit or scope of the present invention. Therefore, the description is considered to be exemplary and non-restrictive in nature.
[0028] Unless otherwise defined herein, scientific and technical terms used in conjunction with the present invention will have the meanings commonly understood by those of ordinary skill in the art. In addition, unless the context otherwise requires, terms in the singular shall include plural forms, and terms in the plural shall include singular forms. More specifically, as used in this specification and the appended claims, unless the context otherwise clearly indicates, the singular forms "one", "an" and "the" include plural indicators. In this application, unless otherwise stated, the use of "or" means "and / or". In addition, the use of the term "comprising" and other forms (such as "including" and "containing") is not restrictive. In addition, the ranges provided in the specification and the appended claims include all values between the endpoints and the endpoints. The preferred embodiments of the present invention are described below, and it should be understood that the preferred embodiments described herein are only used to illustrate and explain the present invention and are not used to limit the present invention.
[0029] definition
[0030] In order to better understand the present invention, definitions and explanations of relevant terms are provided below.
[0031] The term "drugs containing protein molecules" refers to drugs whose main active ingredients are proteins or polypeptides (such as antibodies) and drugs whose main active ingredients are partly proteins or polypeptides (such as ADCs). In addition, "drugs containing protein molecules" also include drugs whose inactive ingredients are proteins or polypeptides.
[0032] The term "antibody" or "Ab" generally refers to a Y-shaped tetrameric protein comprising two heavy (H) and two light (L) polypeptide chains held together by covalent disulfide bonds and non-covalent interactions. The light chains of antibodies can be divided into κ or λ light chains. The heavy chains can be divided into μ, δ, γ, α or ε, which define the isotype of the antibody as IgM, IgD, IgG, IgA or IgE, respectively. In the light and heavy chains, the variable region is connected to the constant region by a "J" region of about 12 or more amino acids, and the heavy chain also contains a "D" region of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of 3 domains (CH1, CH2 and CH3). Each light chain consists of a light chain variable region (VL) and a light chain constant region (CL). The VH and VL regions can be further divided into hypervariable regions (called complementary determining regions, CDRs) separated by relatively conserved regions (called framework regions, FRs). Each VH and VL consists of 3 CDRs and 4 FRs in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4 from N-terminus to C-terminus. The variable regions (VH and VL) of each heavy chain / light chain pair form the antigen binding site / part, respectively.
[0033] Antibodies in the present disclosure also include antigen binding portions (interchangeably used with the term "antigen binding fragment"). Antigen binding portions refer to polypeptides comprising fragments of intact antibodies that retain the ability to specifically bind to an antigen that specifically binds to a full-length or intact antibody, and / or that compete with a full-length antibody for binding to the same antigen. Under some conditions, antigen binding portions include Fab, Fab', F(ab')2, Fd, Fv, dAb and complementary determining region (CDR) fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabodies, and antibodies that contain at least a portion of an antibody sufficient to confer specific antigen binding ability to a polypeptide. The antigen binding portion of an antibody can be obtained from a given antibody by conventional techniques known to those skilled in the art (e.g., recombinant DNA techniques or enzymatic or chemical cleavage methods), and can be screened for specificity in the same manner as intact antibodies.
[0034] The term "antibody-drug conjugate (ADC)" refers to a small molecule drug with biological activity connected to an antibody through a chemical chain, and the antibody acts as a carrier to transport the small molecule drug into the target cell. In some embodiments, the molecular formula of the antibody-drug conjugate is: Ab-[LD]n, where Ab represents an antibody (e.g., an anti-CLDN18.2 antibody), an antigen-binding fragment thereof, or a variant thereof, L represents a linker, D represents a drug, and n represents the average number of drug connections relative to each molecule of Ab. In some embodiments, the linker L is a cysteine-coupled linker, a lysine-coupled linker, a valine-citrulline (Val-Cit, vc) linker, an SPDB linker, an SMCC linker, or a SMAC (sortasemediated antibody conjugation technology) linker.
[0035] The term "Claudin18.2": The Claudin (CLDN) protein family is an important component and functional structure of the tight junction complex (TJs), including at least 27 family members, and is a transmembrane protein located on the surface of the cell membrane. Its structure includes 4 transmembrane regions and 2 cell-shaped ring structures, and the amino and carboxyl termini are located in the cytoplasm. The role of Claudin protein in cancer is mainly: low expression can enhance the transport and invasion of tumor cells, and overexpression may lead to abnormal localization and function in certain cancers. Claudin18.2 (Claudin18 subtype 2) is encoded by the CLDN18 gene and belongs to the Claudin protein family. In the present invention, "Claudin18.2 ADC" refers to an antibody-drug conjugate that can target the Claudin18.2 target. In addition, herein, the terms "claudin18.2 antibody", "CLDN18.2 antibody", "anti-claudin18.2 antibody" and "anti-CLDN18.2 antibody" can be used interchangeably.
[0036] The term "SEC" refers to size exclusion chromatography (SEC), which is a technique that is usually used to separate substances with a molecular weight greater than 2000 according to their molecular size. As an important branch of liquid chromatography, the most widely used application of SEC is to determine the molecular weight distribution of synthetic polymers; it is also an effective separation and purification method for certain macromolecular samples such as proteins and nucleic acids. SEC can easily and quickly separate simple mixtures with large molecular weight differences among sample components.
[0037] The term "iCIEF" refers to capillary isoelectric focusing electrophoresis, which is a highly efficient technique for analyzing protein charge isomers. With iCIEF, researchers can accurately separate and identify proteins or peptides with different isoelectric points (pI). iCIEF uses capillary isoelectric focusing technology to establish a stable pH gradient in the capillary, so that proteins migrate to their isoelectric point under the action of the electric field and focus into sharp bands. When the isoelectric point is reached, the net charge of the protein is zero and the migration rate slows down, thereby achieving the separation of different charge isomers.
[0038] The term "DAR" refers to the drug-to-antibody ratio, which is a derivative term unique to ADC drugs. It is defined as the drug / antibody ratio, which is the average amount of drug carried by an antibody. DAR is the result of balancing efficacy and safety. The antibody-drug conjugation ratio (DAR) is one of the most important quality attributes of ADC. DAR determines the "payload" that can be delivered to the tumor, which directly affects the safety and effectiveness of ADC.
[0039] Liquid pharmaceutical preparation and preparation method thereof
[0040] One aspect of the present invention relates to a pharmaceutical liquid preparation, which comprises a drug, an excipient component and water, wherein the excipient component comprises a surfactant, a protective agent, and optionally comprises a buffer salt system, wherein the drug is a drug containing a protein molecule, preferably an antibody, and more preferably an antibody-drug conjugate (ADC).
[0041] The liquid drug preparation of the present invention uses a protective agent and a surfactant in combination as a stability protective agent for the drug, which helps to keep the protein molecules of the drug structurally stable in the liquid preparation and is not easily degraded, so that there are fewer impurities in the liquid preparation.
[0042] In some embodiments, the protective agent is selected from at least one of trehalose, mannitol, sodium chloride, arginine hydrochloride, proline, glycine and mixtures thereof. In a preferred embodiment, the protective agent preferably comprises sucrose.
[0043] The inventors have found that protective agents such as trehalose, mannitol, sodium chloride, arginine hydrochloride, proline, glycine, and especially sucrose can more significantly ensure the structural stability of the drug and prevent it from being easily degraded.
[0044] In some embodiments, the surfactant is selected from one or both of polysorbate 20 and polysorbate 80. The present invention finds that polysorbate 20 and / or polysorbate 80 are suitable for compatibility with protective agents such as sucrose, and can have a more significant synergistic effect in maintaining the structural stability of the drug.
[0045] In some embodiments, the buffer salt system is selected from a phosphate buffer system, a citrate buffer system, a succinate buffer system and a histidine / histidine hydrochloride buffer system. In a more preferred embodiment, the buffer salt system is a histidine / histidine hydrochloride buffer system.
[0046] The stability of the liquid preparation can be further improved by further using the above buffer salt system (especially histidine / histidine hydrochloride), making the liquid preparation more stable within a suitable pH range.
[0047] In some embodiments, the drug is an antibody, preferably an antibody-drug conjugate (ADC). In a specific embodiment, the drug is Claudin18.2 ADC.
[0048] In some embodiments, in the Claudin18.2 ADC, the amino acid sequence of the complementary determining region HCDR1 of the heavy chain variable region (VH) of the Claudin18.2 antibody is as shown in SEQ ID NO.1, the amino acid sequence of HCDR2 is as shown in SEQ ID NO.2, and the amino acid sequence of HCDR3 is as shown in SEQ ID NO.3. Wherein, SEQ ID NO.1 is NYEMN; SEQ ID NO.2 is YITGSGRTIYYADSVKG; SEQ ID NO.3 is YDYGDFDF. The amino acid sequence of the complementary determining region LCDR1 of the light chain variable region (VL) is as shown in SEQ ID NO.4, the amino acid sequence of LCDR2 is as shown in SEQ ID NO.5, and the amino acid sequence of LCDR3 is as shown in SEQ ID NO.6. Wherein, SEQ ID NO.4 is RASQGISSWLA; SEQ ID NO.5 is AASSLQS; SEQ ID NO.6 is QQANSFPLT.
[0049] In some embodiments, the amino acid sequence of the heavy chain variable region (VH) of the Claudin18.2 antibody is as shown in SEQ ID NO.7, and the amino acid sequence of the light chain variable region (VL) is as shown in SEQ ID NO.8. Wherein, SEQ ID NO.7 is QVQLVESGG GLVQPGGSLRLSCAASGFTFSNYEMNWVRQAPGKGLEWVAYITGSGRTIYYADSVKGRFTISRD NAKKSLYLQMNSLRSEDTAVYYCAIYDYGDFDFWGQGTLVTVSS; SEQ ID NO.8 is DIQMTQS PSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL TISSLQPEDFATYYCQQANSFPLTFGGGTKVEIK.
[0050] In one embodiment, the Claudin18.2 antibody further comprises a heavy chain constant region and a light chain constant region. Preferably, the heavy chain constant region is selected from the IgG series of antibodies (e.g., one or more of IgG1, IgG2, and IgG4). In a specific embodiment, the heavy chain constant region is IgG1, IgG2, or IgG4. Preferably, the light chain constant region is selected from κ or λ chain. In one embodiment, the light chain constant region is a κ chain. In another embodiment, the light chain constant region is a λ chain.
[0051] In the above preparations, the protein concentration of the drug is 5-30 mg / mL, for example, 8-26 mg / mL, 10-25 mg / mL, 12-20 mg / mL, for example 8, 9, 10, 11, 12, 13, 14, 15, 16 mg / mL, etc.
[0052] In the above preparation, the concentration of the protective agent (such as sucrose) is 120-240mmol / L, preferably 150-220mmol / L, such as 125mmol / L, 140mmol / L, 160mmol / L, 170mmol / L, 180mmol / L, 190mmol / L, 200mmol / L, 240mmol / L, etc.
[0053] In the above preparation, the concentration of the surfactant is 0.1-0.5 mg / mL, for example, 0.15 mg / mL, 0.2 mg / mL, 0.3 mg / mL, 0.4 mg / mL or 0.45 mg / mL.
[0054] In the above preparation, the buffer salt concentration is 5-15mmol / L, for example, 5.5mmol / L, 7mmol / L, 8mmol / L, 9mmol / L, 10mmol / L, 11mmol / L, 12mmol / L, 14mmol / L, etc.
[0055] In some preferred embodiments, the pharmaceutical preparation contains 10-20 mg / mL (e.g., 20 mg / mL) antibody-drug conjugate, 180-220 (e.g., 200) mmol / L sucrose, 0.15-0.3 (e.g., 0.2) mg / mL polysorbate 80, 8-12 (e.g., 10) mmol / L histidine / histidine hydrochloride, based on protein concentration. In a specific embodiment, the liquid preparation contains 20 mg / mL Claudin18.2 ADC, 200 mmol / L sucrose, 0.2 mg / mL polysorbate 80, 10 mmol / L histidine / histidine hydrochloride, and the rest is water.
[0056] The pH of the above-mentioned liquid drug preparation is 4.5-6.5, for example, pH is 5.0-6.0, 4.8-5.8, such as pH=4.9, pH=5.0, pH=5.1, pH=5.2, pH=5.3, pH=5.4 or pH=5.5, etc. Other specific point values within this numerical range can be selected, and they will not be described one by one here.
[0057] Another aspect of the present invention relates to a method for preparing the above-mentioned liquid drug preparation, comprising mixing the drug with the above-mentioned auxiliary material components and water, dissolving the components by stirring, etc., and further packaging the liquid preparation into different specifications (e.g., 5 ml or 10 ml per bottle) as needed.
[0058] Dry powder preparation of medicine and preparation method thereof
[0059] Another aspect of the present invention provides a drug dry powder preparation, which comprises the above-mentioned drug and the above-mentioned auxiliary material components.
[0060] In some embodiments, the dry powder preparation is prepared by drying the pharmaceutical liquid preparation of the present invention. In a specific embodiment, the drying is spray drying. In a preferred embodiment, the drying is freeze drying.
[0061] As an example of freeze-drying, the following steps or stages are included: placing the liquid drug preparation described in the first aspect in a container, and sequentially undergoing a first pre-freezing stage, a second pre-freezing stage, a third pre-freezing stage (annealing), a fourth pre-freezing stage, a first drying stage, a second primary drying stage, secondary drying, a pressure rise test and gas filling in a freeze dryer to obtain the dry powder preparation.
[0062] Preferably, the plate temperature in the first stage of pre-freezing is -10 to -2°C, for example, -10°C, -8°C, -6°C, -5°C, -4°C, -3°C or -2°C, etc., among which -7 to -6°C is preferred; the cooling time is 10-40min, for example, 10min, 15min, 20min, 25min, 30min, 35min, 40min, among which 20 to 30min is preferred; the insulation time is 70-110min, for example, 70min, 75min, 80min, 85min, 90min, 95min, 100min, 105min, 110min, among which 80 to 100min is preferred; other specific point values within the above numerical range can be selected, and they will not be repeated here.
[0063] Preferably, the plate temperature in the second stage of pre-freezing is -50 to -30°C, for example, -50°C, -48°C, -45°C, -42°C, -39°C, -36°C, -33°C or -30°C, among which -45 to -40°C is preferred; the cooling time is 60-100min, for example, 60min, 65min, 70min, 75min, 80min, 85min, 90min, 95min, 100min, among which 70 to 90min is preferred; the insulation time is 160 to 200min, for example, 160min, 165min, 170min, 175min, 180min, 185min, 190min, 195min, 200min, among which 170 to 190min is preferred; other specific point values within the above numerical range can be selected, and they will not be described one by one here.
[0064] Preferably, the plate temperature in the third stage of pre-freezing is -20 to -5°C, for example, -20°C, -18°C, -16°C, -15°C, -12°C, -10°C, -8°C or -5°C, among which -15 to -5°C is preferred; the cooling time is 50 to 90 min, for example, 50 min, 55 min, 60 min, 65 min, 70 min, 75 min, 80 min, 85 min, 90 min, among which 60 to 80 min is preferred; the insulation time is 160 to 200 min, for example, 160 min, 165 min, 170 min, 175 min, 180 min, 185 min, 190 min, 195 min, 200 min, among which 170 to 190 min is preferred; the cavity pressure is normal pressure, and other specific point values within the above numerical range can be selected, which will not be repeated here. This step, as a freeze-drying annealing process, makes the freeze-dried product tend to form a more thermodynamically stable state, so that more amorphous components are transformed into a crystalline state, and the crystallization rate is improved. Some components with a lower glass transition temperature are transformed into a crystalline state, and the glass transition temperature of the sample as a whole is increased. After the overall glass transition temperature is increased, a higher sublimation temperature can be used in the sublimation process, shortening the sublimation time.
[0065] Preferably, the plate temperature in the fourth stage of pre-freezing is -50 to -30°C, for example, -50°C, -48°C, -45°C, -42°C, -39°C, -36°C, -33°C or -30°C, among which -45 to -35°C is preferred; the cooling time is 50 to 90 min, for example, 50 min, 55 min, 60 min, 65 min, 70 min, 75 min, 80 min, 85 min, 90 min, among which 60 to 80 min is preferred; the insulation time is 200 to 280 min, for example, 200 min, 210 min, 220 min, 230 min, 240 min, 250 min, 260 min, 270 min, 280 min, among which 220 to 260 min is preferred; other specific point values within the numerical range can be selected, and they will not be described one by one here.
[0066] Preferably, the board layer temperature in the first stage of the primary drying is -40 to -20°C, for example, -40°C, -38°C, -35°C, -30°C, -25°C, -20°C, etc., among which -30 to -25°C is preferred; the heating time is 60-100min, for example, 60min, 65min, 70min, 75min, 80min, 85min, 90min, 95min, 100min, among which 70 to 90min is preferred; the insulation time is 3300 to 3500min, for example, 3300min, 3350min, 3400min, 3450min, 3500min, among which 3350 to 3450min is preferred; other specific point values within the above numerical range can be selected, and they will not be repeated here.
[0067] Preferably, the board layer temperature in the second stage of the primary drying is -35 to -15°C, for example, -35°C, -30°C, -25°C, -20°C, -15°C, etc., among which -30 to -20°C is preferred; the heating time is 5-35min, for example, 5min, 10min, 15min, 20min, 25min, 30min, 35min, among which 10 to 30min is preferred; the insulation time is 400 to 800min, for example, 400min, 450min, 500min, 550min, 600min, 650min, 700min, 750min, 800min, among which 500 to 700min is preferred; other specific point values within the above numerical range can be selected, and they will not be repeated here.
[0068] Preferably, the temperature of the board layer during the secondary drying is 20-40°C, for example, 20°C, 25°C, 30°C, 35°C or 40°C, etc., among which 25-35°C is preferred; the heating time is 90-130min, for example, 90min, 95min, 100min, 105min, 110min, 115min, 120min, 125min, 130min, among which 100-120min is preferred; the insulation time is 400-800min, for example, 400min, 450min, 500min, 550min, 600min, 650min, 700min, 750min, 800min, among which 500-700min is preferred; other specific point values within the above numerical range can be selected, and they will not be repeated here one by one.
[0069] Preferably, the freeze-drying chamber pressure in the primary drying stage and the secondary drying stage is independently 10-35Pa, for example, 10Pa, 15Pa, 20Pa, 25Pa, 30Pa or 35Pa, etc., among which 15-25Pa is preferred; other specific point values within this numerical range can be selected and will not be described one by one here.
[0070] Preferably, the pressure rise test holding time is 2-10min, for example 2min, 4min, 5min, 8min, 10min, etc., among which 4-8min is preferred; other specific point values within this numerical range can be selected, and the pressure rise range is ≤5Pa, which will not be repeated here.
[0071] Preferably, the gas in the gas filling step is nitrogen or air; preferably nitrogen filling.
[0072] Preferably, the nitrogen filling pressure is -0.01 to -0.05 MPa, for example, -0.01 MPa, -0.02 MPa, -0.03 MPa, -0.04 MPa, -0.05 MPa, etc., among which -0.02 to -0.04 MPa is preferred; the pressure increase range is ≤5 Pa, and other specific point values within the numerical range can be selected, which will not be described one by one here.
[0073] Preferably, the bottom area of the container is 3-6 cm 2 For example, a SCHOTT 1832965 20 ml vial or a NIPROA 12120C402 20 ml vial can be used as the container.
[0074] Preferably, the amount of the liquid drug preparation in the container is 4.5-5.5 mL, for example, 4.5 mL, 4.6 mL, 4.7 mL, 4.8 mL, 4.9 mL, 5.0 mL, 5.1 mL, 5.2 mL, 5.3 mL, 5.4 mL or 5.5 mL, and other specific point values within this numerical range can be selected, which will not be described one by one here.
[0075] Through the above exemplary freeze-drying method, the freeze-dried product can have a good appearance and low moisture content in a short freeze-drying time. The appearance is still good after reconstitution, and the product has good stability. Therefore, after the thermal acceleration test, the main quality indicators such as protein concentration, SEC purity, nrCE-SDS purity iCIEF, DAR value, moisture, visible foreign matter, insoluble particles, etc. have no obvious changes and meet the quality standards.
[0076] Example
[0077] The invention generally described herein will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended to limit the invention. In addition, the experimental methods in the following examples are conventional methods unless otherwise specified. The raw materials, reagent materials, etc. used in the following examples are commercially available products unless otherwise specified.
[0078] Screening Experiment Summary
[0079] “T0” represents the state after sample preparation is completed and no thermal acceleration test is carried out.
[0080] Appearance evaluation mainly examines the color and clarity of the samples.
[0081] The protein concentration in the drug was measured using an ultraviolet measuring instrument, and the protein activity was measured using the fibrin plate lysis circle method.
[0082] SEC-HPLC adopts the four-part area normalization method of the 2020 edition of the Chinese Pharmacopoeia.
[0083] nrCE-SDS refers to the general chapter 0542 capillary electrophoresis method and general chapter 3127 monoclonal antibody molecular size variant determination method in Part IV of the 2020 edition of the Chinese Pharmacopoeia.
[0084] The free drug determination (LC-MSD method; using Agilent 1290 InfinityⅡ ultra high performance liquid chromatography (UHPLC) system and Agilent 6125C single quadrupole mass spectrometer), reconstitution time (timing), iCIEF (whole-column imaging capillary isoelectric focusing; Protein Simple Maurice capillary isoelectric focusing detector), and MFI (microfluidic imaging; ProteinSimple MFI5200 microfluidic imager) were determined using equipment-specific methods.
[0085] Sample and reagent information
[0086]
[0087] Among them, the Claudin18.2 antibody sequence is shown in the following table.
[0088]
[0089]
[0090] The following target proteins were detected using Claudin18.2 ADC.
[0091] pH screening test
[0092] Sample Information
[0093]
[0094] Experimental results and analysis
[0095] Preparation pH Screening Test-pH
[0096]
[0097]
[0098] Preparation pH Screening Test - Visible Foreign Matter
[0099] Formulation pH Screening Test-Protein Concentration
[0100] Formulation pH Screening Test - Particle Concentration
[0101] Formulation pH Screening Test-SEC Purity
[0102]
[0103] Preparation pH Screening Test nrCE Purity
[0104] Formulation pH Screening Test - rCE Purity
[0105] Formulation pH Screening Test-HIC
[0106]
[0107]
[0108] From the results in the above table, it can be seen that after the seven groups of samples were accelerated at 40°C for 3 weeks, there were no significant differences in pH, visible foreign matter, protein concentration, and CE purity. The MFI results showed that the levels of insoluble particles in samples 1-7 were relatively high, but could be reduced by adding surfactants. The SEC results showed that the SEC purity decreased with the increase of pH. The HIC results showed that the DAR values of samples 5 (pH6.3) and 6 (pH6.5) decreased by 0.3, and there was no significant difference in the DAR values of the remaining samples, all decreasing by 0.2. There was little difference in the various inspection items between samples 4 and 7.
[0109] Excipient ingredient screening test
[0110] Sample Information
[0111]
[0112] Experimental results and analysis
[0113] Preparation excipient screening test-pH
[0114]
[0115] Preparation excipient screening test-visible foreign matter
[0116]
[0117] Preparation excipient screening test-protein concentration
[0118]
[0119]
[0120] Pharmaceutical Excipient Screening Test-Particle Concentration
[0121] Preparation excipient screening test-SEC purity
[0122] Preparation excipient screening test nrCE purity
[0123]
[0124] Preparation excipient screening test-rCE purity
[0125]
[0126]
[0127] Preparation excipient screening test-HIC
[0128]
[0129] Preparation excipient screening test-osmotic pressure
[0130]
[0131] Preparation excipient screening test - repeated freeze-thaw - SEC
[0132]
[0133] From the results in the table above, it can be seen that among the carbohydrate excipients, after 4 weeks of acceleration at 40°C, there is no significant difference between sucrose and trehalose as protective agents in maintaining protein purity and maintaining protein particle stability. Sucrose can be selected as a freeze-drying protective agent from the perspective of economic cost. Among the surfactant excipients, the particle level of the sample containing polysorbate 20 is relatively high, and polysorbate 80 can reduce the particle level of the sample and there is no visible foreign matter after acceleration. After adding the excipients, repeated freezing and thawing for 5 times had no significant effect on the SEC purity of the product. In addition, no significant difference was found in the accelerated test results of different drug concentrations (measured by protein concentration).
[0134] Liquid sample accelerated experimentSample information: The target protein concentration in the following samples is 20 mg / ml
[0135]
[0136] Experimental results and analysis
[0137] Liquid Sample Inspection-Visible Foreign Matter
[0138]
[0139] Liquid Sample Investigation-pH and Osmotic Pressure
[0140]
[0141] Liquid Sample Investigation-Protein Concentration
[0142]
[0143] Liquid Sample Inspection-SEC Purity
[0144]
[0145]
[0146] Liquid sample to examine nrCE purity
[0147] Liquid Sample Inspection-rCE Purity
[0148]
[0149] Liquid Sample Inspection-HIC
[0150]
[0151] Liquid Sample Inspection-iCIEF
[0152]
[0153]
[0154] Liquid Sample Investigation-Free Drug
[0155]
[0156] Freeze drying process
[0157] First round of freeze-drying process optimization
[0158] Sample Information:
[0159]
[0160] Tc (collapse temperature) and Tg' (glass transition temperature) detection
[0161] First round of freeze-drying optimization parameters
[0162]
[0163]
[0164] Results of the first round of freeze-drying optimization test
[0165]
[0166] As can be seen from the above table, the moisture content of the drug liquid preparation sample after the first round of freeze-drying is lower than that of the control (formulation buffer) sample without drug, and the appearance is good.
[0167] Second round of freeze-drying process parameters
[0168]
[0169]
[0170]
[0171] It can be seen from the above table that a more ideal freeze-drying effect (low moisture content and good appearance) was obtained when the freeze-drying time was shortened compared to the previous round.
[0172] The third round of freeze-drying research
[0173] The third round of freeze-drying process parameters
[0174]
[0175]
[0176] Results of the third round of freeze-drying optimization test
[0177]
[0178] It can be seen from the above table that there is no obvious change in the moisture content of the protein sample after this round of freeze-drying, but the moisture content of the freeze-dried preparation buffer sample is slightly higher than that of the previous two rounds, and the appearance of the freeze-dried protein sample shows bottom shrinkage, and the appearance of the freeze-dried preparation buffer sample shows partial collapse. It is speculated that this is caused by the incomplete sublimation of moisture in the first stage of the first drying, the excessively high plate temperature in the second stage, and the insufficient bottom support force caused by the upward migration of the solute.
[0179] Freeze-drying process confirmation
[0180] According to the parameters of the second round of freeze-drying process, in order to ensure the good shape of the product, the time of the second stage of primary drying is increased in this round of full-box freeze-drying process.
[0181] Freeze-drying process confirmation parameters
[0182]
[0183]
[0184] Freeze-drying process confirmation results
[0185]
[0186] It can be seen from the above table that the samples produced by this round of freeze-drying process have low moisture content and good appearance. At the same time, the freeze-drying time is relatively short, which is a more robust freeze-drying process.
[0187] Evaluation of freeze-thaw stability, high temperature and light stability of lyophilized powder preparations
[0188] In the subsequent filling process, the above-mentioned lyophilized powder preparation was subjected to repeated freeze-thaw experiments, stirring experiments, and short-term stability experiments. The results showed that repeated freeze-thaw experiments five times at ≤60°C, continuous stirring for 1 hour at a level where a vortex was just visible on the liquid surface, and storage at 2-8°C and 25°C±2°C for 7 days had no significant effect on the quality of the stock solution.
[0189] In the experiment on the influencing factors of the above freeze-dried powder preparations, the results of high temperature and light intensity experiments showed that acceleration at 40°C for 4 weeks and illumination for 12 days (5000±500lx) had little effect on the quality of the finished products, indicating that the finished products had good high temperature and light stability.
[0190] Accelerated stability test of preparations
[0191] The dry powder formulations prepared in the following Examples 1-4 were subjected to thermal accelerated stability evaluation.
[0192] The freeze-drying process parameters used in Examples 1-4 are shown in the following table.
[0193]
[0194]
[0195] Example 1
[0196] The liquid preparation and lyophilized preparation of Example 1 are prepared as follows:
[0197] Using water as solvent, the concentrations of each component were prepared as 10 mmol / L histidine / histidine hydrochloride, 200 mmol / L sucrose, 0.2 mg / mL polysorbate 80, pH 5.1, and the protein (Claudin18.2 ADC) concentration was 20 mg / mL. The mixture was stirred evenly to obtain a liquid preparation containing Claudin18.2 ADC.
[0198] After sterilizing and filtering, the liquid preparations were placed in containers suitable for freeze-drying (SCHOTT 1832965 20 ml vials in this embodiment), 5 ml / vial, and freeze-dried according to the freeze-drying process parameters to obtain the freeze-dried preparation of Example 1.
[0199] Example 2
[0200] The liquid preparation and lyophilized preparation of Example 2 are prepared as follows:
[0201] Using water as solvent, the concentrations of each component were prepared as 10 mmol / L histidine / histidine hydrochloride, 200 mmol / L sucrose, 0.2 mg / mL polysorbate 80, pH 5.3, and the protein (Claudin18.2 ADC) concentration was 20 mg / mL. The mixture was stirred evenly to obtain a liquid preparation containing Claudin18.2 ADC.
[0202] After sterilizing and filtering the liquid preparation, the preparation was freeze-dried in the same manner as in Example 1 to obtain the freeze-dried preparation of Example 2.
[0203] Example 3
[0204] The liquid preparation and lyophilized preparation of Example 3 are prepared as follows:
[0205] Using water as solvent, the concentrations of each component were prepared as 10 mmol / L histidine / histidine hydrochloride, 200 mmol / L sucrose, 0.2 mg / mL polysorbate 80, pH 5.5, and the protein (Claudin18.2 ADC) concentration was 20 mg / mL. The mixture was stirred evenly to obtain a liquid preparation containing Claudin18.2 ADC.
[0206] After sterilizing and filtering the above liquid preparation, it was freeze-dried in the same manner as in Example 1 to obtain the freeze-dried preparation of Example 3.
[0207] Example 4
[0208] The liquid preparation and lyophilized preparation of Example 4 are prepared as follows:
[0209] Using water as solvent, the concentrations of each component were prepared as 10 mmol / L histidine / histidine hydrochloride, 200 mmol / L sucrose, 0.2 mg / mL polysorbate 80, pH 5.7, and the protein (Claudin18.2 ADC) concentration was 20 mg / mL. The mixture was stirred evenly to obtain a liquid preparation containing Claudin18.2 ADC.
[0210] After sterilizing and filtering the liquid preparation, the preparation was freeze-dried in the same manner as in Example 1 to obtain the freeze-dried preparation of Example 4.
[0211] Accelerated stability test
[0212] The following stability indicators were evaluated for the Claudin18.2 ADC freeze-dried preparations obtained in Examples 1-4 after being placed at 0°C and 30°C or 40°C:
[0213] Appearance: Check the color and clarity of the sample;
[0214] The ADC drug protein concentration was measured using an ultraviolet instrument; the protein activity was measured using the fibrin plate lysis circle method.
[0215] SEC-HPLC adopts the four-part area normalization method of the 2020 edition of the Chinese Pharmacopoeia.
[0216] nrCE-SDS refers to the general chapter 0542 capillary electrophoresis method and general chapter 3127 monoclonal antibody molecular size variant determination method in Part IV of the 2020 edition of the Chinese Pharmacopoeia.
[0217] The free drug determination (LC-MSD method; using Agilent 1290 InfinityⅡ ultra high performance liquid chromatography (UHPLC) system and Agilent 6125C single quadrupole mass spectrometer), reconstitution time (timing), iCIEF (whole-column imaging capillary isoelectric focusing; Protein Simple Maurice capillary isoelectric focusing detector), and MFI (microfluidic imaging; ProteinSimple MFI5200 microfluidic imager) were determined using equipment-specific methods.
[0218] The results are shown in the following table:
[0219] Appearance:
[0220]
[0221] According to the appearance test results, there is no significant difference in the appearance of the freeze-dried powder and the reconstituted samples of Examples 1-4 at 0 hours, after accelerated at 40°C for 2 weeks (2W) and 4 weeks (4W).
[0222] Moisture:
[0223]
[0224] According to the appearance test results, there is no significant difference in the freeze-dried moisture of the samples of Examples 1-4 at 0 hours, after 2 weeks and after 4 weeks of acceleration at 40°C.
[0225] Reconstitution time:
[0226]
[0227] According to the appearance test results, there is no significant difference in the freeze-dried reconstitution time of samples of Examples 1-4 at 0 hours, 40°C for 2 weeks, and 4 weeks.
[0228] pH and osmotic pressure after reconstitution:
[0229]
[0230] According to the appearance test results, there is no significant difference in pH and osmotic pressure after freeze-drying and reconstitution of samples of Examples 1-4 at 0 hours, 40°C for 2 weeks, and 4 weeks, and they are all within the target value range.
[0231] Protein concentration:
[0232]
[0233] According to the appearance test results, the protein concentration of samples of Examples 1-4 after freeze-drying and reconstitution at 0 hours, 40°C for 2 weeks, and 4 weeks did not change significantly.
[0234] SEC Purity:
[0235]
[0236] According to the appearance test results, the SEC of samples of Examples 1-4 at 0 hours, after 2 weeks and 4 weeks of acceleration at 40°C, did not change significantly.
[0237] Coupling rate (HIC):
[0238]
[0239] According to the HIC test results, compared with time 0, the coupling rates of the four groups of samples did not change significantly after being accelerated at 40°C for 2 weeks and 40°C for 4 weeks, and there was no significant difference between the groups.
[0240] nrCE purity
[0241]
[0242]
[0243] According to the non-reduced CE-SDS purity test results, compared with time 0, the non-reduced purity of the four groups of samples did not change significantly after being accelerated at 40°C for 2 weeks and 40°C for 4 weeks, and there was no significant difference between the groups.
[0244] nrCE purity
[0245]
[0246] According to the results of reduced CE-SDS purity test, compared with time 0, the reduced purity of the four groups of samples did not change significantly after being accelerated at 40°C for 2 weeks and 40°C for 4 weeks, and there was no significant difference between the groups.
[0247] MFI
[0248]
[0249] According to the MFI test results, compared with time 0, the levels of insoluble particles in the four groups of samples were lower after being accelerated at 40℃ for 2 weeks and 40℃ for 4 weeks, and there was no significant difference between the groups.
[0250] iCIEF
[0251]
[0252]
[0253] According to the iCIEF test results, compared with time 0, the acidic peak proportion, main peak proportion and alkaline peak proportion of the four groups of samples did not change significantly after being accelerated at 40°C for 4 weeks, and there was no significant difference between the groups.
[0254] Free drug:
[0255]
[0256] According to the free drug test results, no free drugs were detected in the four groups of samples at 0 time, after 2 weeks of acceleration at 40°C, and after 4 weeks of acceleration at 40°C.
[0257] Binding activity:
[0258]
[0259] According to the binding activity test results, the binding activities of the four groups of samples were within the acceptable range at 0 time, after 2 weeks of acceleration at 40°C, and after 4 weeks of acceleration at 40°C.
[0260] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for a person skilled in the art to modify the technical solutions described in the aforementioned embodiments or to replace some of the technical features therein by equivalents. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included in the protection scope of the present invention. In addition, although the elements of the present invention may be described or required in individual form, it is also conceivable to have multiple elements unless explicitly limited to a single element.
Claims
1. A pharmaceutical liquid preparation comprising a drug, an auxiliary component and water, wherein the auxiliary component comprises a surfactant, a protective agent and optionally a buffer salt system, wherein the drug is a drug containing a protein molecule, preferably an antibody, and more preferably an antibody-drug conjugate (ADC).
2. The liquid pharmaceutical preparation according to claim 1, characterized in that: The surfactant is selected from one or both of polysorbate 20 and polysorbate 80; preferably, the protective agent is selected from one of trehalose, sucrose, mannitol, sodium chloride, arginine hydrochloride, proline, glycine and a mixture thereof, wherein the protective agent preferably comprises sucrose; preferably, the buffer salt system is selected from a phosphate buffer system, a citrate buffer system, a succinate buffer system and a histidine / histidine hydrochloride buffer system (wherein the histidine / histidine hydrochloride buffer system is preferred).
3. The liquid pharmaceutical preparation according to claim 1 or 2, characterized in that: The drug is an antibody-drug conjugate (ADC), such as Claudin18.2 ADC; Preferably, in the Claudin18.2 ADC, the heavy chain variable region of the Claudin18.2 antibody comprises HCDR1 as shown in SEQ ID NO.1, HCDR2 as shown in SEQ ID NO.2, and HCDR3 as shown in SEQ ID NO.3; the light chain variable region comprises LCDR1 as shown in SEQ ID NO.4, LCDR2 as shown in SEQ ID NO.5, and LCDR3 as shown in SEQ ID NO.6; Further preferably, the Claudin18.2 antibody further includes a heavy chain variable region as shown in SEQ ID NO.7; and a light chain variable region as shown in SEQ ID NO.8; preferably, the Claudin18.2 antibody also includes a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region is selected from the IgG series antibodies (for example, one or more of IgG1, IgG2 and IgG4); the light chain constant region is selected from κ or λ chain.
4. A pharmaceutical liquid formulation according to any one of the preceding claims, characterized in that In the preparation, the protein concentration of the drug is 5-30 mg / mL, preferably, the protective agent concentration is 120-240 mmol / L, preferably, the surfactant concentration is 0.1-0.5 mg / mL, preferably, the buffer salt concentration is 5-15 mmol / L, preferably, the pH of the liquid preparation is 4.5-6.5, for example, pH 5.0-6.0, 4.8-5.8, for example 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.
6.
5. A pharmaceutical liquid formulation according to any one of the preceding claims, characterized in that The liquid preparation contains, in terms of protein concentration, 10-20 mg / mL (e.g., 20 mg / mL) of antibody-drug conjugate, 180-220 (e.g., 200) mmol / L of sucrose, 0.15-0.3 (e.g., 0.2) mg / mL of polysorbate 80, and 8-12 (e.g., 10) mmol / L of histidine / histidine hydrochloride. Preferably, the drug is Claudin18.2 ADC.
6. A method for preparing a liquid pharmaceutical preparation according to any one of claims 1 to 5, comprising mixing the drug (eg, Claudin18.2 ADC) with the excipient ingredients and water.
7. A dry powder preparation, characterized in that: The dry powder preparation comprises the drug and auxiliary material components as described in any one of claims 1 to 5. Preferably, the dry powder preparation is prepared by drying (for example, freeze-drying) the drug liquid preparation as described in any one of claims 1 to 5.
8. A method for preparing a dry powder preparation, characterized in that: The method comprises the following steps: freeze-drying the liquid pharmaceutical preparation according to any one of claims 1 to 5.
9. The method for preparing the dry powder preparation according to claim 8, wherein the freeze-drying comprises: Pre-freezing first stage, pre-freezing second stage, pre-freezing third stage (annealing), pre-freezing fourth stage, primary drying first stage, primary drying second stage, secondary drying, pressure rise test and gas filling steps.
10. The method for preparing the dry powder preparation according to claim 9, characterized in that: The plate temperature in the first stage of pre-freezing is -10 to -2°C, the cooling time is 10 to 40 minutes, and the heat preservation time is 70 to 110 minutes; wherein the plate temperature in the first stage of pre-freezing is preferably -7 to -6°C, the cooling time is preferably 20 to 30 minutes, and the heat preservation time is preferably 80 to 100 minutes; And / or, the plate layer temperature in the second stage of pre-freezing is -50 to -30°C, the cooling time is 60-100 min, and the heat preservation time is 160 to 200 min; wherein the plate layer temperature in the second stage of pre-freezing is preferably -45 to -40°C, the cooling time is preferably 70 to 90 min, and the heat preservation time is preferably 170 to 190 min; And / or, the plate layer temperature in the third stage of pre-freezing is -20 to -5°C, the cooling time is 50 to 90 minutes, and the heat preservation time is 160 to 200 minutes; wherein the plate layer temperature in the third stage of pre-freezing is preferably -15 to -5°C, the cooling time is preferably 60 to 80 minutes, and the heat preservation time is preferably 170 to 190 minutes; And / or, the plate layer temperature in the fourth stage of pre-freezing is -50 to -30°C, the cooling time is 50 to 90 minutes, and the heat preservation time is 200 to 280 minutes; wherein the plate layer temperature in the fourth stage of pre-freezing is preferably -45 to -35°C, the cooling time is preferably 60 to 80 minutes, and the heat preservation time is preferably 220 to 260 minutes; And / or, the board temperature in the first stage of the primary drying is -40 to -20°C, the heating time is 60 to 100 minutes, and the heat preservation time is 3300 to 3500 minutes; wherein the board temperature in the first stage of the primary drying is preferably -30 to -25°C, the heating time is preferably 70 to 90 minutes, and the heat preservation time is preferably 3350 to 3450 minutes; And / or, the temperature of the board layer in the second stage of the primary drying is -35 to -15°C, the heating time is 5 to 35 minutes, and the insulation time is 400 to 800 minutes; wherein the temperature of the board layer in the second stage of the primary drying is preferably -30 to -20°C, the heating time is preferably 10 to 30 minutes, and the insulation time is preferably 500 to 700 minutes; And / or, the temperature of the secondary drying board layer is 20-40°C; the heating time is 90-130min, and the heat preservation time is 400-800min, wherein the temperature of the secondary drying board layer is preferably 25-35°C, the heating time is 100-120min, and the heat preservation time is 500-700min; and / or, the gas in the gas filling step is nitrogen or air; And / or, the freeze-drying chamber pressure in the first pre-freezing stage, the second pre-freezing stage, the third pre-freezing stage and the fourth pre-freezing stage is normal pressure; And / or, the freeze-drying chamber pressure in the primary drying stage and the secondary drying stage is 10-35 Pa, preferably 15-25 Pa; And / or, the pressure rise test holding time is 2-10 minutes, preferably 4-8 minutes; the pressure rise range is ≤5Pa; and / or, the gas filling pressure is -0.01 to -0.05 MPa, preferably -0.02 to -0.04 MPa; the pressure increase range is ≤5 Pa; and / or, the bottom area of the container for placing the freeze-dried preparation is 3-6 cm 2 ; And / or, the amount of the liquid pharmaceutical preparation in the container is 4.5-5.5 mL.
